Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Oditrasertib in Amyotrophic Lateral Sclerosis: NCT05797701 Clinical Landscape Report 2026
16 October 2026
NCT05797701 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tombestomig in Locally Advanced Renal Cell Carcinoma: NCT05805501 Clinical Landscape Report 2026
16 October 2026
NCT05805501 clinical landscape for Locally Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Atorvastatin Calcium in Metastatic Renal Cell Carcinoma: NCT05796973 Clinical Landscape Report 2026
16 October 2026
NCT05796973 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DCTY-0801 in Recurrent Glioblastoma: NCT05802693 Clinical Landscape Report 2026
16 October 2026
NCT05802693 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axitinib in Advanced Renal Cell Carcinoma: NCT05808608 Clinical Landscape Report 2026
16 October 2026
NCT05808608 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Triple Negative Breast Cancer: NCT05806385 Clinical Landscape Report 2026
16 October 2026
NCT05806385 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Advanced Triple-Negative Breast Carcinoma: NCT05809895 Clinical Landscape Report 2026
16 October 2026
NCT05809895 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Axitinib in Metastatic Renal Cell Carcinoma: NCT05816642 Clinical Landscape Report 2026
16 October 2026
NCT05816642 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute) in Triple Negative Breast Cancer: NCT05809752 Clinical Landscape Report 2026
16 October 2026
NCT05809752 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Recurrent Glioblastoma: NCT05811793 Clinical Landscape Report 2026
16 October 2026
NCT05811793 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Florbetapir F-18 in Glioblastoma Multiforme: NCT05820191 Clinical Landscape Report 2026
16 October 2026
NCT05820191 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Metastatic Renal Cell Carcinoma: NCT05817903 Clinical Landscape Report 2026
16 October 2026
NCT05817903 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.